Prospective, multi-centric, randomized open-label, two arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-033 / Erbitux in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck
Latest Information Update: 03 Jul 2019
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Reliance Life Sciences
- 14 Jan 2019 Status changed from recruiting to discontinued.
- 31 Aug 2016 New trial record